Compared with those in the IR group, IL-34 treatment significantly increased myocardial infarction size (0.36 ± 0.022 vs 0.67 ± 0.020, p<0.05) and led to increased serum cTnI (76.16 ± 3.26 ng/ml vs 34.12 ± 2.40 ng/ml, p<0.05) and serum CK-Mb (2756.92 ± 78.08 ng/ml vs 1679.13 ± 49.58 ng/mL, p<0.05) levels. This evidence concerns the gene TNNI3 and myocardial infarction.